title: [Contribution of an induction treatment in the surgical treatment of locally advanced non-small-cell cancers].
abstract: From October 1988 to July 1990, 18 patients with marginally resectable non-small cell cancer (10 stage IIIa and 8 stage IIIb) were entered in a phase-II trial combining induction therapy with a subsequent thoracotomy. Induction therapy included 2 courses of chemotherapy (5-FU and cisplatinum) and radiotherapy (30 Gray in split course). Partial response was observed in 10 patients, and minimal response in 3. Thoracotomy disclosed unresectability in 3 patients. Fifteen complete resections consisted in 1 lobectomy and 14 pneumonectomies. There were no operative deaths (30 days). Postoperative recovery was uneventful in 3 patients with exploratory thoracotomy and in 1 patient with lobectomy. Following pneumonectomy, we observed 2 bronchopleural fistulae and 1 empyema. On pathology, 10 patients were stage IIIa, and 3 were stage I, whereas no residual tumor was found in 2 patients. During follow-up, local recurrence occurred in 2, and metastases in 8. On December 31st, 1993, 3 patients were alive at 44, 52, and 62 months respectively. Nine patients had died from cancer, and 3 from unrelated causes. Estimated survival was 66.7% at 1 year, 33.3% at 3 years, and 20% at 5 years. We conclude that induction therapy allowed satisfactory resection for marginally resectable tumors. Operative morbidity was increased in this group. However, the 5-year survival was similar to resectable stage IIIa cancer.
authors.affiliation: Service de Chirurgie Thoracique, Hôpitaux Universitaires de Strasbourg.
authors.forename: G
authors.initials: G
authors.lastname: Massard
authors.forename: B
authors.initials: B
authors.lastname: Sohier
authors.forename: G M
authors.initials: GM
authors.lastname: Jung
authors.forename: A
authors.initials: A
authors.lastname: Dietemann
authors.forename: R
authors.initials: R
authors.lastname: Kessler
authors.forename: P
authors.initials: P
authors.lastname: Dumont
authors.forename: P
authors.initials: P
authors.lastname: Fraisse
authors.forename: A
authors.initials: A
authors.lastname: Charloux
authors.forename: C
authors.initials: C
authors.lastname: Bohner
authors.forename: J M
authors.initials: JM
authors.lastname: Wihlm
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011300:Preoperative Care; D011879:Radiotherapy Dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D002945:Cisplatin; D005472:Fluorouracil
vernacular_title: Apport d'un traitement d'induction dans le traitement chirurgical des cancers non microcellulaires localement avancés.